Navigation Links
MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
Date:12/20/2011

ROCKVILLE, Md., Dec. 20, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, announced today that it will receive a milestone payment from Boehringer Ingelheim.  The milestone payment was triggered as part of an agreement executed in October 2010 to discover, develop and commercialize antibody-based therapeutics based on MacroGenics' Dual-Affinity Re-Targeting (DART) platform.  The amount of the milestone payment remained undisclosed.  Therapeutics in the global alliance will be directed against up to ten combinations of molecular targets and may span multiple therapeutic areas, including immunology, oncology, respiratory, cardiometabolic and infectious diseases.  To date, MacroGenics has achieved five pre-clinical milestones across both of its DART collaborations with Boehringer Ingelheim and Pfizer, Inc.

Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics, commented: "We are very encouraged by the progress we've made with this DART candidate in collaboration with Boehringer Ingelheim."  Dr. Koenig continued, "MacroGenics expects to advance multiple product candidates from this alliance in 2012 and beyond."

About MacroGenics
MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for cancer, autoimmune disorders and infectious diseases. The company has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' proprietary research is based on three core technology platforms, which include: (1) a leading research capability for screening and targeting cancer stem-like cells; (2) Dual-Affinity Re-Targeting (or DART) bispecific technology, which allows the incorporation of multiple specificities within a single recombinant molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions.  The company has research and development collaborations with multiple, major pharmaceutical companies including Boehringer Ingelheim, Les Laboratoires Servier and Pfizer, Inc.  For more information about MacroGenics, please visit www.macrogenics.com.

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as MacroGenics' ability to raise additional capital, and risks related to its ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. MacroGenics assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.

 

 

 


'/>"/>
SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid Tumors
2. MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer
3. MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances DART Platform and Infectious Disease Portfolio
4. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
5. Paulo F. Costa Joins MacroGenics Board of Directors
6. MacroGenics Appoints New Vice President of Business Development
7. MacroGenics Raises $25M in Series D-2 Financing
8. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
9. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
10. Watsons Generic Yaz(R) Receives FDA Approval
11. UCSB professor receives award for graphene electronics research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... for clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT ... care circle with the physician and clinical trial team. , Using the CONSULT module, ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
Breaking Biology News(10 mins):